Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Antiviral Activity of Alfosbuvir (SH229) in Chronic HCV
NCT03588923Phase 1Completed
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aoxibuvir in hepatitis C (HCV) (3 cohorts), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Incidence of adverse events at Day 10 and Antiviral effects of SH229 at Day 10. Started Jul 2018; status: completed.
02
Drugs
aoxibuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03588923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588923.